The present invention relates to a humanized antibody or functional
fragment thereof which binds to a mammalian (e.g., human) CC-chemokine
receptor 2 (CCR2) or a portion of the receptor and blocks binding of a
ligand to the receptor. The invention further relates to a method of
inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand
thereof, and to use of the antibodies and fragments in therapeutic,
prophylactic and diagnostic methods.
